



PROMISES TO ASHES FOUNDATION

Resource Center Education Module: Synthetic 7-OH Derivatives

These compounds are not the same thing as natural kratom leaf or every concentrated 7-OH product.

WHAT THIS CATEGORY MEANS

In July 2026, FDA and DEA materials separately identified three synthetic 7-OH derivatives that do not naturally occur in the kratom plant: **mitragynine pseudoindoxyl (MP)**, **MGM-15**, and **MGM-16**. These substances belong in their own education category so the public is not taught to use the word 'synthetic' too broadly.

THE THREE SPECIFICALLY IDENTIFIED DERIVATIVES

COMPOUND	WHAT FAMILIES SHOULD UNDERSTAND
Mitragynine pseudoindoxyl (MP)	Identified by FDA/DEA as a synthetic 7-OH derivative that does not naturally occur in the kratom plant.
MGM-15	Identified by FDA/DEA as a synthetic 7-OH derivative; it should not be confused with naturally occurring kratom alkaloids simply because it is discussed in the same regulatory action.
MGM-16	Also identified by FDA/DEA as a synthetic 7-OH derivative and treated separately from botanical kratom in the federal materials.

WHY LANGUAGE MATTERS

The Foundation should not call every concentrated 7-OH product 'synthetic.' FDA distinguishes products with added or enhanced 7-OH from these specifically identified synthetic derivatives, while DEA has also used the term **semi-synthetic 7-OH** when describing certain commercial products. Our public materials will preserve those distinctions rather than collapse them into one label.

CURRENT FEDERAL ACTION

FDA reported that on July 1, 2026 DEA announced the start of a temporary-scheduling process for 7-OH above a proposed specified threshold and for MP, MGM-15, and MGM-16. DEA's announcement says these substances were being addressed under the Controlled Substances Act process. Regulatory status can change, so any public statement about scheduling should be checked again before publication.

WHAT PARENTS SHOULD LOOK FOR

These names are more likely to appear in technical, ingredient, laboratory, regulatory, or product-description language than in familiar consumer terminology. Families should focus on the actual substance name when it is disclosed and avoid relying on branding alone.

PROMISES TO ASHES PUBLICATION RULE

Specific compound names must come from authoritative sources. Brand names are examples, not definitions. No product-purchase links or commercial pathways are permitted.

PRIMARY EDUCATIONAL SOURCES

FDA - Hiding in Plain Sight: 7-OH Products
<https://www.fda.gov/news-events/public-health-focus/hiding-plain-sight-7-oh-products>

DEA - DEA to Temporarily Schedule 7-OH and Related Substances to Protect the Public
<https://www.dea.gov/press-releases/2026/07/01/dea-temporarily-schedule-7-oh-and-related-substances-protect-public>

Educational information only. No product promotion. No purchase pathways. Sources are reviewed for accuracy and updated as evidence and regulations change.

For Justin, and for every family after.